- Home
- DBX vs IONS Comparison
DBX vs IONS Comparison
Compare DBX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBX
- IONS
- Stock Information
- Founded
- DBX 2007
- IONS 1989
- Country
- DBX United States
- IONS United States
- Employees
- DBX N/A
- IONS N/A
- Industry
- DBX Computer Software: Prepackaged Software
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- DBX Technology
- IONS Health Care
- Exchange
- DBX Nasdaq
- IONS Nasdaq
- Market Cap
- DBX 8.3B
- IONS 6.8B
- IPO Year
- DBX 2018
- IONS 1991
- Fundamental
- Price
- DBX $29.07
- IONS $68.65
- Analyst Decision
- DBX Hold
- IONS Buy
- Analyst Count
- DBX 6
- IONS 19
- Target Price
- DBX $29.80
- IONS $72.53
- AVG Volume (30 Days)
- DBX 3.5M
- IONS 2.0M
- Earning Date
- DBX 11-06-2025
- IONS 11-05-2025
- Dividend Yield
- DBX N/A
- IONS N/A
- EPS Growth
- DBX N/A
- IONS N/A
- EPS
- DBX 1.57
- IONS N/A
- Revenue
- DBX $2,532,800,000.00
- IONS $944,050,000.00
- Revenue This Year
- DBX N/A
- IONS $24.01
- Revenue Next Year
- DBX N/A
- IONS $4.06
- P/E Ratio
- DBX $18.55
- IONS N/A
- Revenue Growth
- DBX N/A
- IONS 16.05
- 52 Week Low
- DBX $24.42
- IONS $23.95
- 52 Week High
- DBX $33.33
- IONS $70.14
- Technical
- Relative Strength Index (RSI)
- DBX 43.49
- IONS 78.29
- Support Level
- DBX $29.13
- IONS $60.41
- Resistance Level
- DBX $30.24
- IONS $70.14
- Average True Range (ATR)
- DBX 0.72
- IONS 1.66
- MACD
- DBX -0.32
- IONS -0.01
- Stochastic Oscillator
- DBX 7.71
- IONS 86.54
About DBX Dropbox Inc.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.